Inhaled corticosteroids after respiratory syncytial virus infection
Autor: | Mike Sharland, Jenny Handforth, Jon S. Friedland |
---|---|
Rok vydání: | 2009 |
Předmět: |
Pediatrics
medicine.medical_specialty Respiratory Syncytial Virus Infections Azithromycin law.invention chemistry.chemical_compound Randomized controlled trial Adrenal Cortex Hormones law Wheeze Lower respiratory tract infection Administration Inhalation medicine Humans Respiratory system Intensive care medicine General Environmental Science business.industry Ribavirin General Engineering General Medicine medicine.disease chemistry Bronchiolitis Breathing General Earth and Planetary Sciences medicine.symptom business medicine.drug |
Zdroj: | BMJ. 338:b164-b164 |
ISSN: | 1468-5833 0959-8138 |
DOI: | 10.1136/bmj.b164 |
Popis: | Are ineffective and should not be used to prevent subsequent wheeze Respiratory syncytial virus (RSV) infection often causes bronchiolitis in infants, and the season for infection started early this year, perhaps because it has been a cold winter (www.hpa.org.uk). Between 2% and 3% of infants are admitted to hospital with RSV each year. Supportive treatment with fluids, oxygen, and ventilation is still the only management option available because adrenaline, bronchodilators, steroids, ribavirin, and azithromycin offer no benefit or may even be harmful in the acute phase.1 2 3 RSV bronchiolitis can lead to secondary wheeze, and treatment options are also limited in this phase of the disease. In the linked randomised controlled trial (doi:10.1136/bmj.b897), Ermers and colleagues assess whether giving high dose hydrofluoroalkane extrafine beclometasone for three months after hospital admission for lower respiratory tract infection with RSV prevents recurrent wheeze.4 Reactive airways disease can occur after bronchiolitis, with a … |
Databáze: | OpenAIRE |
Externí odkaz: |